全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Kiran Naqvi , Jorge E. Cortes ...
来源:[J].International Journal of Hematology(IF 1.681), 2018, Vol.107 (6), pp.689-695Springer
摘要:Abstract(#br)Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to all TKI. We aimed to study the incidence, prognosis, ...
作者:Maliha Khan , Rabbia Siddiqi , Kiran Naqvi
来源:[J].Annals of Hematology(IF 2.866), 2018, Vol.97 (6), pp.945-953Springer
摘要:Abstract(#br)Mixed phenotype acute leukemia (MPAL) is an uncommon diagnosis, representing only about 2–5% of acute leukemia cases. The blast cells of MPAL express multilineage immunophenotypic markers and may have a shared B/T/myeloid phenotype. Due to historical ambiguity i...
作者:Kiran Naqvi , Farhad Ravandi
来源:[J].Leukemia & Lymphoma(IF 2.301), 2019, Vol.60 (8), pp.1866-1876Taylor & Francis
摘要:Abstract(#br)Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic challenge. Cytogenetics is a well-established prognostic factor. Recent discovery of molecular mutations has gained momentum with some being potential therapeutic targets. FLT3 mutation...
作者:Kiran Naqvi , Naval Daver ...
来源:[J].Leukemia & Lymphoma(IF 2.301), 2017, Vol.58 (4), pp.866-871Taylor & Francis
摘要:Abstract(#br)Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) tr...
作者:Kiran Naqvi , Elias Jabbour ...
来源:[J].American Journal of Hematology(IF 4.003), 2014, Vol.89 (5), pp.509-516Wiley
摘要:Comorbidities significantly affect the prognosis and outcomes of patients with hematological malignancies. We have previously reported the impact of comorbidities on the International Prognostic Scoring System (IPSS) score. The aim of this study was to determine whether como...
作者:Kiran Naqvi , Alfonso Quintas‐Cardama ...
来源:[J].American Journal of Hematology(IF 4.003), 2016, Vol.91 (12), pp.1221-1226Wiley
摘要:In patients with acute myeloid leukemia (AML), rapid reduction of circulating blasts with induction chemotherapy may serve as an in vivo marker of chemosensitivity. We performed a retrospective analysis of 363 patients with untreated AML who received induction chemotherapy i...
作者:Kiran Naqvi , Mark Brandt ...
来源:[J].International Journal of Molecular Sciences(IF 2.464), 2017, Vol.18 (8)MDPI
摘要:(1) Runt-related transcription factor 1 (RUNX1) mutations in acute myeloid leukemia (AML) are often associated with worse prognosis. We assessed co-occurring mutations, response to therapy, and clinical outcomes in patients with and without mutant RUNX1 (mRUNX1); (2) We analyzed ...
作者:Kiran Naqvi , Srdan Verstovsek ...
来源:[J].Expert Opinion on Investigational Drugs(IF 4.744), 2011, Vol.20 (8), pp.1159-1166Informa Healthcare
摘要:Introduction: An increased understanding of cellular signaling pathways, like the JAK–STAT pathway, and the identification of the JAK2 V617F mutation in the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has generated great interest in the deve...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×